<DOC>
	<DOC>NCT02095158</DOC>
	<brief_summary>This study will evaluate the long-term safety and efficacy of oxymetazoline hydrogen chloride (HCL) Cream 1.0% (AGN-199201) in patients with persistent erythema associated with rosacea.</brief_summary>
	<brief_title>A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<criteria>Moderate to severe persistent facial erythema associated with rosacea. Current treatment with monoamine oxidase (MAO) inhibitors Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>